Granulocyte macrophage colony stimulating factor

High incidence of apheresis catheter thrombosis during peripheral stem cell collection

L. C. Stephens, W. D. Haire, K. Schmit-Pokorny, Margaret Anne Kessinger, G. Kotulak

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Granulocyte-macrophage colony stimulating factor (GM-CSF) has been used to augment circulating hemo poietic stem cells in the peripheral blood and promote efficient peripheral stem cell (PSC) collection. Anecdotal reports indicate that GM-CSF may contribute to apheresis catheter dysfunction during PSC collection. We prospectively evaluated thrombotic occlusion rate of inferior vena cava (IVC) catheters following introduction of GM-CSF compared with a control group who underwent PSC collection prior to introduction of GM-CSF. Both groups were given aspirin (325 mg daily). The active treatment group was given GM-CSF (starting dose 250 μg/m2/day) as continuous infusion via the IVC catheter. The rate of thrombotically occluded catheters increased from 1/29 (3%) to 20/37 (54%) (p < 0.0001). Thrombi developing during GM-CSF therapy were unusual as 25/36 (69%) occlusions cleared with mechanical clot aspiration and did not require lytic agents.

Original languageEnglish (US)
Pages (from-to)51-54
Number of pages4
JournalBone marrow transplantation
Volume11
Issue number1
StatePublished - Jan 1 1993

Fingerprint

Blood Component Removal
Granulocyte-Macrophage Colony-Stimulating Factor
Thrombosis
Catheters
Incidence
Inferior Vena Cava
Suction
Aspirin
Peripheral Blood Stem Cells
Control Groups
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Stephens, L. C., Haire, W. D., Schmit-Pokorny, K., Kessinger, M. A., & Kotulak, G. (1993). Granulocyte macrophage colony stimulating factor: High incidence of apheresis catheter thrombosis during peripheral stem cell collection. Bone marrow transplantation, 11(1), 51-54.

Granulocyte macrophage colony stimulating factor : High incidence of apheresis catheter thrombosis during peripheral stem cell collection. / Stephens, L. C.; Haire, W. D.; Schmit-Pokorny, K.; Kessinger, Margaret Anne; Kotulak, G.

In: Bone marrow transplantation, Vol. 11, No. 1, 01.01.1993, p. 51-54.

Research output: Contribution to journalArticle

Stephens, LC, Haire, WD, Schmit-Pokorny, K, Kessinger, MA & Kotulak, G 1993, 'Granulocyte macrophage colony stimulating factor: High incidence of apheresis catheter thrombosis during peripheral stem cell collection', Bone marrow transplantation, vol. 11, no. 1, pp. 51-54.
Stephens, L. C. ; Haire, W. D. ; Schmit-Pokorny, K. ; Kessinger, Margaret Anne ; Kotulak, G. / Granulocyte macrophage colony stimulating factor : High incidence of apheresis catheter thrombosis during peripheral stem cell collection. In: Bone marrow transplantation. 1993 ; Vol. 11, No. 1. pp. 51-54.
@article{7a673c243a9345b1997370f483f43ad1,
title = "Granulocyte macrophage colony stimulating factor: High incidence of apheresis catheter thrombosis during peripheral stem cell collection",
abstract = "Granulocyte-macrophage colony stimulating factor (GM-CSF) has been used to augment circulating hemo poietic stem cells in the peripheral blood and promote efficient peripheral stem cell (PSC) collection. Anecdotal reports indicate that GM-CSF may contribute to apheresis catheter dysfunction during PSC collection. We prospectively evaluated thrombotic occlusion rate of inferior vena cava (IVC) catheters following introduction of GM-CSF compared with a control group who underwent PSC collection prior to introduction of GM-CSF. Both groups were given aspirin (325 mg daily). The active treatment group was given GM-CSF (starting dose 250 μg/m2/day) as continuous infusion via the IVC catheter. The rate of thrombotically occluded catheters increased from 1/29 (3{\%}) to 20/37 (54{\%}) (p < 0.0001). Thrombi developing during GM-CSF therapy were unusual as 25/36 (69{\%}) occlusions cleared with mechanical clot aspiration and did not require lytic agents.",
author = "Stephens, {L. C.} and Haire, {W. D.} and K. Schmit-Pokorny and Kessinger, {Margaret Anne} and G. Kotulak",
year = "1993",
month = "1",
day = "1",
language = "English (US)",
volume = "11",
pages = "51--54",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Granulocyte macrophage colony stimulating factor

T2 - High incidence of apheresis catheter thrombosis during peripheral stem cell collection

AU - Stephens, L. C.

AU - Haire, W. D.

AU - Schmit-Pokorny, K.

AU - Kessinger, Margaret Anne

AU - Kotulak, G.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Granulocyte-macrophage colony stimulating factor (GM-CSF) has been used to augment circulating hemo poietic stem cells in the peripheral blood and promote efficient peripheral stem cell (PSC) collection. Anecdotal reports indicate that GM-CSF may contribute to apheresis catheter dysfunction during PSC collection. We prospectively evaluated thrombotic occlusion rate of inferior vena cava (IVC) catheters following introduction of GM-CSF compared with a control group who underwent PSC collection prior to introduction of GM-CSF. Both groups were given aspirin (325 mg daily). The active treatment group was given GM-CSF (starting dose 250 μg/m2/day) as continuous infusion via the IVC catheter. The rate of thrombotically occluded catheters increased from 1/29 (3%) to 20/37 (54%) (p < 0.0001). Thrombi developing during GM-CSF therapy were unusual as 25/36 (69%) occlusions cleared with mechanical clot aspiration and did not require lytic agents.

AB - Granulocyte-macrophage colony stimulating factor (GM-CSF) has been used to augment circulating hemo poietic stem cells in the peripheral blood and promote efficient peripheral stem cell (PSC) collection. Anecdotal reports indicate that GM-CSF may contribute to apheresis catheter dysfunction during PSC collection. We prospectively evaluated thrombotic occlusion rate of inferior vena cava (IVC) catheters following introduction of GM-CSF compared with a control group who underwent PSC collection prior to introduction of GM-CSF. Both groups were given aspirin (325 mg daily). The active treatment group was given GM-CSF (starting dose 250 μg/m2/day) as continuous infusion via the IVC catheter. The rate of thrombotically occluded catheters increased from 1/29 (3%) to 20/37 (54%) (p < 0.0001). Thrombi developing during GM-CSF therapy were unusual as 25/36 (69%) occlusions cleared with mechanical clot aspiration and did not require lytic agents.

UR - http://www.scopus.com/inward/record.url?scp=0027457244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027457244&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 51

EP - 54

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 1

ER -